Literature DB >> 28297039

Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab.

Amir R Hajrasouliha, Jose M Garcia-Gonzales, Michael J Shapiro, Hawke Yoon, Michael P Blair.   

Abstract

Although intravitreal injection of anti-vascular endothelial growth factor agents (IVA) can induce rapid regression of retinopathy of prematurity (ROP), late reactivation of the ROP can occur in the form of tractional retinal detachment (TRD) from contracted recurrent extraretinal fibrovascular proliferation. The authors report a case of bilateral TRD for recurrent ROP in a 3-year-old, which is the latest-reported reactivation to date. The authors propose that persistent avascular retina in eyes that have undergone IVA for ROP receive laser ablation to prevent late recurrences. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:255-259.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28297039     DOI: 10.3928/23258160-20170301-10

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  17 in total

1.  A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.

Authors:  David K Wallace; Trevano W Dean; Mary Elizabeth Hartnett; Lingkun Kong; Lois E Smith; G Baker Hubbard; Mary Lou McGregor; Catherine O Jordan; Iason S Mantagos; Edward F Bell; Raymond T Kraker
Journal:  Ophthalmology       Date:  2018-06-07       Impact factor: 12.079

Review 2.  [Review of clinical trials in retinopathy of prematurity : Current state and future perspectives].

Authors:  Andreas Stahl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

3.  Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.

Authors:  Tariq Aldebasi; Muataz A Guma; Rabia Bashir; Saif Al Saif; Waleed A Altwaijri; Abdulkareem M Al Bekairy
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

4.  Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.

Authors:  Amir Sternfeld; Safa Rahmani; Jennifer L Rossen; David L Zhang; Yuping D Li; Victor L Quan; Russell Huang; Hawke H Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-12-01       Impact factor: 3.117

5.  Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

Authors:  Sharon F Freedman; Amra Hercinovic; David K Wallace; Raymond T Kraker; Zhuokai Li; Amit R Bhatt; Charline S Boente; Eric R Crouch; G Baker Hubbard; David L Rogers; Deborah VanderVeen; Michael B Yang; Nathan L Cheung; Susan A Cotter; Jonathan M Holmes
Journal:  Ophthalmology       Date:  2022-06-01       Impact factor: 14.277

6.  Reactivation of Retinopathy of Prematurity in Adults and Adolescents.

Authors:  Ogul E Uner; Prethy Rao; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2020-02-11

7.  A Quantitative Severity Scale for Retinopathy of Prematurity Using Deep Learning to Monitor Disease Regression After Treatment.

Authors:  Kishan Gupta; J Peter Campbell; Stanford Taylor; James M Brown; Susan Ostmo; R V Paul Chan; Jennifer Dy; Deniz Erdogmus; Stratis Ioannidis; Jayashree Kalpathy-Cramer; Sang J Kim; Michael F Chiang
Journal:  JAMA Ophthalmol       Date:  2019-07-03       Impact factor: 7.389

8.  Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.

Authors:  Kaveh Fadakar; Mohammadreza Mehrabi Bahar; Hamid Riazi-Esfahani; Afsaneh Azarkish; Afsar Dastjani Farahani; Mostafa Heidari; Fatemeh Bazvand
Journal:  Int Ophthalmol       Date:  2022-01-20       Impact factor: 2.029

Review 9.  Complications of retinopathy of prematurity treatment.

Authors:  Joshua M Barnett; G Baker Hubbard
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

10.  Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

Authors:  Gerard P Barry; Yinxi Yu; Gui-Shuang Ying; Lauren A Tomlinson; Juliann Lajoie; Marilyn Fisher; Gil Binenbaum
Journal:  Ophthalmology       Date:  2020-12-31       Impact factor: 14.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.